FINWIRES · TerminalLIVE
FINWIRES

CIBCは、金価格の高騰を背景に、金開発業者にとって好ましい環境が整うと見ている。

By

-- CIBCキャピタル・マーケッツは、金価格の高騰を背景に、フエルテ・メタルズ（FMT.V）、メリディアン・マイニング（MNO.TO）、テーシス・ゴールド＆シルバー（TAU.V）などの金開発企業にとって、事業環境はますます好転していると述べた。 CIBCによると、金価格の上昇はプロジェクトの経済性を向上させており、旺盛な株式資金調達意欲と記録的なロイヤルティ契約の成立がプロジェクトの推進を支え、バランスシートの柔軟性を高めている。 CIBCは、金セクターにおける最近の統合は、買い手と売り手の期待値のギャップを縮めるのに役立つ可能性があるため、M&Aにとって建設的であると見ている。 CIBCの金関連銘柄分析は、セクター全体を広く見直したものであり、堅実な経済性、建設への確実な道筋、有能な経営陣、そして大きな再評価の可能性という、最も魅力的な組み合わせを提供する銘柄に焦点を当てている。 CIBCはまた、スキーナ・リソーシズ（SKE.TO）の目標株価を58.00カナダドルから60.00カナダドルに引き上げた。

Price: $9.51, Change: $+0.26, Percent Change: +2.81%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL